

2026

Interim Report
for the first quarter

January - March 2026



Interim Report for the first quarter of 2026

January 1 – March 31, 2026

The first quarter in figures

- Net sales amounted to TSEK 36,879 (44,493), which translates to a decrease of 3.6% compared to the first quarter of 2025 at constant exchange rates, or 17.1% in reported figures. The significant divergence in growth rates is entirely attributable to the exchange rate depreciation of the USD relative to the SEK during the comparison periods.
- Gross margin of 91.6% (96.4%), with the decrease deriving, in part, from the lower sales in the period but primarily from temporary mix effects.
- Reported EBIT of TSEK -13,466 (-12,697), with the comparison period affected by LTIP related costs for the 2024-28 program.
- Adjusted EBIT of TSEK -13,389 (-5,563), adjusted for LTIP related costs in both periods.
- Operating expenses were lower than last year, even after LTIP adjustments, with the main driver being the lower sales variable costs. Sales commissions and fees were down to 47.1% (49.3%) of net sales in the period.

- Net result for the period amounted to TSEK -11,473 (-14,577).
- Earnings per share of SEK -0.1 (-0.1).
- Cash flow from operating activities of TSEK -14,866 (-25,874), due to a positive working capital development. The comparison period was negatively affected by MSEK -7 in LTIP related payments.

Significant events during the first quarter

- There were no significant events during the first quarter.

Significant events after the end of the first quarter

- OssDsign provides pre-release update on Q1 2026 performance.

Financial overview

	2026	2025	2025
<i>The group</i>	Jan 1 – Mar 31	Jan 1 – Mar 31	Jan 1 – Dec 31
Net sales, TSEK	36 879	44 493	180 159
Adjusted operating result, TSEK	-13 389	-5 563	-26 499
Operating result, TSEK	-13 466	-12 697	-46 757
Result for the period, TSEK	-11 473	-14 577	-50 988
Equity ratio, %	79%	71%	77%
Earnings per share, SEK	-0.1	-0.1	-0.5
Average number of employees	33.3	31.3	32.0



“ With my appointment as CEO, OssDsign has moved its commercial leadership to the United States, positioning the company to accelerate growth and strengthen direct engagement with key surgeon stakeholders. ”

Reset: Laying the groundwork for accelerated growth

I joined OssDsign as CEO in January, drawn by Catalyst’s strong clinical performance, the robustness of the underlying science, and the significant market opportunity in the U.S. These fundamentals remain firmly intact, and I am confident that the factors contributing to the first quarter’s sales challenges are identifiable and addressable. Reflecting upon the first quarter of 2026, this was not the start of the year I would have wished for, nor do I believe it is acceptable. As previously communicated, revenue for January through March 2026 totaled approximately USD \$4 million or SEK 36.9 million, signifying a decrease of 3.6% in USD terms compared to the same quarter of 2025. It is worth noting that the significant divergence between our USD and SEK results – a 3.6% decline in USD terms versus a 17.1% decline in SEK terms – is entirely attributable to the depreciation of the USD against the SEK during the comparison periods. Adjusted EBIT for the quarter was SEK -13.4 million, with marginal exchange rate impact due to the nature of our cost base. The sales outcome falls short of our expectations and, as communicated prior to this report, is also below market expectations.

The root causes of this shortfall are addressable. Due to the volatile capital market in Q1 2025, a proposed share issue was delayed until June. Consequently, some activities were executed more slowly or paused. Further, a slowdown in recruitment and hiring within the sales team during the latter part of 2025 weighed on sales growth in the fourth quarter of last year, and its effects have carried over into Q1 2026. Building a high-performing commercial organization is not something that can be done overnight, and when the hiring process slows, the impact on forward revenue growth is felt in the following period. That impact materialized this quarter. As we address the culture building point highlighted in our annual report, a number of less highly performing sales employees left the Company and we experienced temporary slowdowns within certain key accounts due to extended contract renegotiations. None of these were isolated events – they converged in the same quarter, which amplified the pressure on the top line.

Unmatched real-world outcomes

I want to clarify that the recent financial results should not reflect badly on the product, the core science, or the market potential. In my view, OssDsign Catalyst should be the number one synthetic bone graft option in the spinal fusion market. The real world clinical data we continue to collect in complex patient groups reinforces the outstanding performance of this bone graft substitute. Catalyst was the first synthetic bone graft approved for interbody use based solely on bone graft data, enabling on-label use in any interbody cage approved for synthetic bone grafts. The real-world outcomes data continues to reinforce this strength. A product with this competitive profile is naturally attracting attention from competitors – and we are making the right clinical, marketing and sales investments to ensure OssDsign is a fierce competitor in this market.

Corrective measures underway


We have implemented concrete measures to energize and focus our hiring process and are seeking to consistently expand the sales team with high caliber, driven individuals. With my appointment, commercial leadership is based in the US and can address issues promptly and more effectively. In addition to managing and developing the US organization, I am able to support the sales endeavors directly by interacting in person with key opinion leaders, distributors and hospital systems as a result of being in the market and on the same time zone.

OssDsign continues to align and expand the commercial team, strengthening the sales foundation. Over the past 90 days, there has been excellent progress in identifying and hiring new commercial team members. The ramp-up for newly hired territory managers typically takes several months to translate into meaningful revenue, but the groundwork has been laid this quarter. Additionally, intensive dialogue has been held with several key accounts that faced slowdowns due to contract renegotiations. These discussions are advancing, and it is anticipated that purchasing patterns will return to normal once the agreements are finalized.

Transparency continues to be a key factor

As OssDsign's new CEO, one of my first commitments to this organization and our shareholders has been to foster an open, bold, and dynamic culture. I joined OssDsign because I believe in the product and the opportunities ahead. I remain genuinely confident in the company's potential to deliver increased sales and to create value for shareholders while benefitting patients. That journey has just begun. Looking ahead, the orthobiologics market for spinal fusion is large, growing, and increasingly receptive to the differentiated, evidence-based positioning and unique properties that Catalyst offers. We have the right product, we are building the right team, we are investing in additional clinical data, and the existing clinical data continues to speak for itself. With a sharpened focus on commercial execution, the Company remains confident of hitting the SEK 400 million revenue target set out in the ScaleToProfit strategy. The first step will be delivering improved commercial momentum in the second half of 2026 and I look forward to reporting on that in the coming quarters.

Mark Waugh, CEO



Statement of Operations

OssDsign is a developer and provider of next generation orthobiologic products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve.

OssDsign Catalyst – an off-the-shelf nanosynthetic bone graft

Nearly 80% of Americans experience low back pain at some point in their lives and more than 1.5 million undergo spinal surgery each year, of which approximately half will need fusion surgery. Today approximately 20% of these surgeries are unsuccessful due to the lack of proper fusion (non-union). Bone graft plays a crucial role in the surgery to stimulate bone growth. The major advances provided by orthobiologic products are resulting in a shift in spinal surgery, as the use of synthetic bone graft substitutes has become more common to avoid the need to utilise allograft or iliac crest autograft.

Traditional synthetic materials share similarities with bone tissue at a macro level, rather than on a nano level, leading to a less effective bone formation response. OssDsign Catalyst is a latest-generation nanosynthetic bone graft composed of a proprietary nano-crystalline silicate calcium phosphate. Being similar to the body's own bone mineral architecture, OssDsign Catalyst provides a favorable bone biology environment for rapid and reliable bone formation.

Clear commercial advantages

OssDsign Catalyst is a high gross margin product with great scalability and large potential in the market for standard procedures, enabling extensive growth. OssDsign Catalyst received FDA clearance in 2020 and has been very well received in the U.S. market since its launch in August 2021. By the end of May 2025, more than 10,000 patients had been treated with OssDsign Catalyst in the U.S.

Improved patient outcomes

OssDsign Catalyst received FDA clearance in 2020 based on preclinical results from the most established and demanding non-clinical model for spinal fusion – the Boden model. OssDsign Catalyst surpasses results typically seen with other synthetic bone grafts used in this model.

This has also been confirmed in the clinical study TOP FUSION where top-line results show a 93% spinal fusion rate at 12 months after surgery and 100% at 24 months after surgery with the novel nanosynthetic bone graft. All scores used to quantify pain, function and overall health in patients showed improvement in quality of life over time and no device-related adverse events were observed during the study. This is also in line with the first post-market safety report that was published in November 2022, which did not record any device-related complaints or adverse events.

The data indicates that the use of OssDsign Catalyst leads to consistent and rapid bone healing and remodeling, with improved patient outcomes as a result. Altogether, OssDsign Catalyst has the proven potential to improve the success rates of spinal surgeries – a much-welcomed development for the millions of patients who require a spinal fusion to regain an active and healthy life.

Subsequently, the positive findings outlined here have been further corroborated by additional preclinical research, published in the Journal of Orthopaedic Surgery and Research, as well as clinically, from the first 108 patient readout from our PROPEL registry, showing an 88.4% fusion rate in a highly complex patient cohort.

USD 1.8 billion

The U.S. market value for orthobiologics in spinal surgeries.

Development of profit and financial position

FIRST QUARTER

Sales and Gross margin

The OssDsign Group net sales for the first quarter of 2026 amounted to TSEK 36,879 (44,493), which translates to a decrease of 3.6% compared to the first quarter of 2025 at constant exchange rates, or 17.1% in reported figures. The significant divergence in growth rates is entirely attributable to the exchange rate depreciation of the USD relative to the SEK, from 10.6 to 9.1, during the comparison periods.

Gross margin of 91.6%, compared to 96.4% in the first quarter of 2025, with the decrease deriving from a number of temporary effects. Product and customer mix are variable in nature and both developed unfavourably in the first quarter. In addition, the lower sales in the quarter triggered negative COGS effects, as did the USD/SEK exchange rate development, given the time lag between production and consumption.

Operating result

The Operating result for the period January – March 2026 amounted to TSEK -13,466 (-12,697), with the comparison period affected by LTIP related costs for the 2024-28 program. Adjusted operating result of TSEK -13,389 (-5,563), adjusted for LTIP related costs in both periods, is consequential to the lower sales and gross margin, with some mitigation offered by lower operating expenses. The effects of exchange rate changes at the EBIT level were marginal, due to the nature of our cost base, with the positive impact on operating expenses offsetting the negative impact on sales and COGS.

Operating expenses were lower in the quarter, compared to the same period in the previous year, even after adjustment for LTIP related costs in both periods. The main driver behind this positive deviation was the lower sales variable costs, with the relatively lower sales commissions and fees being down to 47.1% (49.3%) of net sales in the period.

Cash flow, investments and financial position

Cash at the beginning of the period amounted to TSEK 191,346 and at the end of the period TSEK 170,484. Cash flow from operating activities of TSEK -14,866 (-25,874) demonstrated a positive working capital development, with the comparison period negatively affected by SEK -7 million in LTIP related payments.

Cash flow from investments of TSEK -6,012 (-1,305) was considerably higher than previous quarters, driven entirely by investments in new product development.

Total cash flow for the period was TSEK -21,038 (-22,674). No investments in tangible fixed assets in the period, whereas new product development costs were capitalized to the amount of TSEK -6,012 (-857) as intangible assets.


SIGNIFICANT EVENTS DURING THE FIRST QUARTER

There were no significant events during the first quarter.

SIGNIFICANT EVENTS AFTER THE END OF THE FIRST QUARTER

OssDsign provides pre-release update on Q1 2026 performance

On April 10 OssDsign announced that preliminary revenue for the period January – March, 2026 will be USD 4.035 million or SEK 36.880 million. The company attributes these results to a lack of sales channel expansion in late 2025, departure of certain sales personnel, and temporary slowdowns in key accounts due to contract negotiations.



OTHER DISCLOSURES

Ownership structure

Owners	Number of shares	Share Capital, %
Försäkringsaktiebolaget Avanza Pension	11 755 889	10.6%
Linc AB	11 104 396	10.0%
TAMT AB	8 980 000	8.1%
FSG Fund	8 000 000	7.2%
SIX SIS AG, W8IMY	5 573 170	5.0%
La Financière de l'Echiquier - LFDE	4 629 084	4.2%
Nordea Livförsäkring Sverige AB	4 009 705	3.6%
Protean Funds	3 417 401	3.1%
AGB KRONOLUND AKTIEBOLAG	3 000 000	2.7%
OLAUSSON THOMAS	2 403 732	2.2%
Other shareholders	47 752 536	43.2%
Total	110 625 913	100.00%

Group structure

OssDsign AB is the parent company of the Group which, in addition to OssDsign AB, consists of the wholly owned subsidiaries OssDsign Ltd with its registered office in England, OssDsign USA Inc with its registered office in Maryland, USA, and Sirakoss Ltd with its registered office in Scotland. OssDsign's operations are mainly conducted through the parent company OssDsign AB, based in Uppsala, with the sales activities being conducted solely through OssDsign USA Inc.

Employees

At the end of the period, there were a total of 35 (32) employees, of whom 34% were women. This includes employees in Sweden, the U.K. and the U.S.

Financing

The Board regularly reviews the company's existing and forecasted cash flows to ensure that the company has the funds and resources required to conduct the business and the strategic direction decided by the Board. The company's long-term cash requirements are largely determined by how successful current and future products will be on the market. In order to satisfy requirements in the medium to long term, the company raised SEK 158 million in gross proceeds through a directed share issue in 2025. As of March 31, 2026, the group's cash and cash equivalents amounted to SEK 170.5 million. The board deems the current liquidity to be sufficient for at least the next twelve months. Based on the sales development of the company's products the board has confidence in the company's mid- to

long-term ability to become profitable and cash flow positive.

Transactions with related parties

The subsidiaries OssDsign USA Inc, OssDsign Ltd and Sirakoss Ltd invoice their costs to the parent company in accordance with transfer pricing agreements.

As of the closing date, the Parent Company has a net claim on OssDsign USA Inc of TSEK 17,138 and a liability to Sirakoss Ltd of TSEK 1,465.

Risks and uncertainties

OssDsign risks and uncertainties include, but are not limited to, financial risks such as future financing, foreign exchange and credit risks. In addition to market risks, there are risks related to OssDsign operations, such as obtaining the necessary government licenses, product development, patents and intellectual property rights, product liability and forward-looking information that may affect the Company.

In addition, developments in recent years have also introduced war, inflation, energy cost increases, interest rate risks, trade barriers and global instability to the agenda, all of which may come to affect access to raw materials, distribution, cost of goods and services, as well as customer demand and access to capital. Further information regarding the Company's risk exposure can be found on pages 36-37 and 78-81 of the OssDsign Annual Report 2025.

The direction towards protectionism expressed by the U.S. administration can conceivably affect OssDsign's operations going forward. The US import tariffs, as communicated to date, however, are not deemed to have any material impact on the Group's future earnings or financial position.

Parent company

In the first quarter of 2026, the parent company's Net sales amounted to TSEK 6,936 (10,386). As all end customer sales are made from OssDsign USA Inc, the parent company sales are entirely intra-group.

The parent company's EBIT for the first quarter 2026 amounted to TSEK -13,345 (-14,015).

At the end of the period, there were a total of 3 (4) employees in the parent company, of whom 67% were women. This includes only employees in Sweden.

Condensed consolidated income statement

SEK 000'	2026	2025	2025
	Jan 1 - Mar 31	Jan 1 - Mar 31	Jan 1 - Dec 31
Net sales	36 879	44 493	180 159
Cost of sales	-3 104	-1 618	-6 691
Gross profit	33 775	42 875	173 468
Sales commissions and fees	-17 364	-21 942	-87 484
Selling expenses	-14 492	-11 756	-47 874
R&D expenses	-4 169	-5 853	-20 118
Administrative expenses	-11 072	-16 145	-66 350
Other operating income	-	124	1 603
Other operating expense	-143	-	-
Operating result	-13 466	-12 697	-46 757
Net financial items	1 909	-1 976	-3 397
Result before income tax	-11 557	-14 673	-50 154
Income tax	83	96	-835
RESULT FOR THE PERIOD	-11 473	-14 577	-50 988

Condensed consolidated statement of comprehensive income

SEK 000'	2026	2025	2025
	Jan 1 - Mar 31	Jan 1 - Mar 31	Jan 1 - Dec 31
Profit/loss for the period	-11 473	-14 577	-50 988
Items that will be reclassified subsequently to profit or loss	232	-1 269	-17 379
Other comprehensive income for the period	232	-1 269	-17 379
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	-11 242	-15 847	-68 367

Condensed consolidated balance sheet

	2026	2025	2025
SEK 000'	March 31	March 31	Dec 31
ASSETS			
<i>Fixed assets</i>			
Intangible assets	155 348	161 075	150 029
Tangible fixed assets	1 679	1 838	1 906
Financial assets	136	144	132
Total fixed assets	157 163	163 057	152 067
<i>Current assets</i>			
Inventories	21 140	16 049	22 678
Accounts receivable	21 739	23 876	26 131
Tax receivable	–	239	–
Other receivables	385	300	590
Prepayments	6 593	4 164	5 061
Cash and cash equivalents	170 484	77 487	191 346
Total current assets	220 341	122 115	245 806
TOTAL ASSETS	377 504	285 172	397 873

	2026	2025	2025
SEK 000'	March 31	March 31	Dec 31
SHAREHOLDER EQUITY AND LIABILITIES			
Equity	298 866	203 074	310 031
Total equity	298 866	203 074	310 031
<i>Long-term liabilities</i>			
Lease liabilities	156	789	403
Other liabilities	52 018	57 419	52 172
Total long-term liabilities	52 174	58 208	52 575
<i>Current liabilities</i>			
Mortgage debts	–	86	–
Accounts payable	6 467	4 541	5 327
Lease liabilities	1 007	596	969
Tax liability	2	–	48
Other current liabilities	3 943	3 160	10 002
Accrued expenses and deferred income	15 046	15 508	18 922
Total current liabilities	26 465	23 890	35 268
Total liabilities	78 639	82 098	87 843
TOTAL EQUITY AND LIABILITIES	377 504	285 172	397 873

Condensed consolidated change in shareholder's equity

<i>SEK 000'</i>	Share Capital	Other Capital Contributions	Reserves	Profit (loss) brought forward	Total Equity
Opening balance 2025-01-01	6 104	796 024	30 843	-618 908	214 061
Profit/loss for the period	-	-	-	-14 577	-14 577
Other comprehensive income	-	-	-1 269	-	-1 269
Total comprehensive income	-	-	-1 269	-14 577	-15 846
<i>Transactions with shareholders</i>					
Warrant program	-	-	-	4 859	4 859
Total transactions with shareholders	-	-	-	4 859	4 859
CLOSING BALANCE 2025-03-31	6 104	796 024	29 574	-628 625	203 074
Opening balance 2026-01-01	6 914	954 366	13 464	-664 711	310 031
Profit/loss for the period	-	-	-	-11 473	-11 473
Other comprehensive income	-	-	232	-	232
Total comprehensive income	-	-	232	-11 473	-11 241
<i>Transactions with shareholders</i>					
Warrant programmes	-	-	-	77	77
Total transactions with shareholders	-	-	-	77	77
CLOSING BALANCE 2026-03-31	6 914	954 366	13 696	-676 107	298 866

Condensed consolidated statement of cash flow

SEK 000'	2026	2025	2025
	Jan 1 – Mar 31	Jan 1 – Mar 31	Jan 1 – Dec 31
Operating activities			
Operating result	-13 466	-12 697	-46 757
Non cash adjustment	957	918	-788
Financial items	1 909	-1 976	-3 397
Income taxes paid/received	-104	-108	-1 393
	-10 705	-13 863	-52 335
Changes in inventories	1 779	-2 981	-10 182
Changes in receivables	3 776	-626	-6 243
Changes in current liabilities	-9 716	-8 405	4 725
Total change in working capital	-4 161	-12 012	-11 699
Cash flow from operating activities	-14 866	-25 874	-64 034
Investment activities			
Proceeds and purchase of intangible assets, net	-6 012	-857	-6 723
Proceeds and purchase of property, plant and equipment, net	-	-448	-677
Cash flow from investment activities	-6 012	-1 305	-7 400
Financing activities			
New share issue	-	-	168 086
Share issue costs	-	-	-8 934
Warrants	77	4 859	5 185
Proceeds/repayments from borrowings, net	-	-128	-214
Repayment of lease liabilities	-238	-226	-945
Cash flow from financing activities	-161	4 505	163 178
Cash flow for the period	-21 038	-22 674	91 743
Cash and cash equivalents at the beginning of the period	191 346	100 858	100 858
Exchange rate adjustments – cash, cash equivalents and overdrafts	176	-697	-1 255
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	170 484	77 487	191 346

Condensed income statement, parent company

<i>SEK 000'</i>	2026	2025	2025
	Jan 1 – Mar 31	Jan 1 – Mar 31	Jan 1 – Dec 31
Net sales	6 936	10 386	25 023
Cost of goods sold	-3 955	-4 376	-11 389
Gross profit	2 981	6 010	13 633
Sales commissions and fees	-403	-832	-2 695
Selling expenses	-474	-125	-1 041
R&D expenses	-8 030	-5 841	-20 357
Administrative expenses	-7 419	-13 227	-47 812
Other operating income	-	-	1 353
Operating result	-13 345	-14 015	-56 919
Net financial items	1 912	-1 974	-3 390
Result before income tax	-11 433	-15 989	-60 309
Income tax	-	-	-
RESULT FOR THE PERIOD	-11 433	-15 989	-60 309

Condensed consolidated statement of comprehensive income, parent company

<i>SEK 000'</i>	2026	2025	2025
	Jan 1 – Mar 31	Jan 1 – Mar 31	Jan 1 – Dec 31
Profit/loss for the period	-11 433	-15 989	-60 309
Items that will be reclassified subsequently to profit or loss	-	-	-
Other comprehensive income for the period	-	-	-
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	-11 433	-15 989	-60 309

Condensed balance sheet, parent company

	2026	2025	2025
SEK 000'	Mar 31	Mar 31	Dec 31
ASSETS			
<i>Fixed assets</i>			
Financial assets	137 687	137 687	137 687
Total fixed assets	137 687	137 687	137 687
<i>Current assets</i>			
Inventories	18 665	13 193	20 563
Intercompany receivables	19 785	13 941	14 032
Tax receivable	467	467	363
Other receivables	328	300	468
Prepayments	3 264	2 987	1 989
Cash and cash equivalents	161 796	71 172	182 351
Total current assets	204 306	102 058	219 765
TOTAL ASSETS	341 993	239 746	357 452

	2026	2025	2025
SEK 000'	Mar 31	Mar 31	Dec 31
SHAREHOLDER EQUITY AND LIABILITIES			
<i>Equity</i>			
Equity	275 699	172 300	287 132
Total equity	275 699	172 300	287 132
<i>Provisions</i>			
Other provisions	50 072	54 701	50 072
Total provisions	50 072	54 701	50 072
<i>Current liabilities</i>			
Mortgage debts	–	86	–
Accounts payable	5 064	3 220	2 579
Intercompany liabilities	4 112	1 493	1 838
Other current liabilities	3 731	3 053	9 780
Accrued expenses and deferred income	3 316	4 894	6 052
Total current liabilities	16 223	12 745	20 249
Total liabilities	66 295	67 446	70 321
TOTAL EQUITY AND LIABILITIES	341 993	239 746	357 452

Notes

Note 1 | Accounting Principles

This summary interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and applicable regulations in the Swedish Annual Accounts Act. The interim report for the Parent Company has been prepared in accordance with the Swedish Annual Accounts Act chapter 9, Interim Financial Reporting. The same accounting and valuation policies have been applied for the Group and the Parent Company as in the latest Annual Report. Disclosures in accordance with IAS 34.16A occur in the financial reports and the accompanying notes, and also in other parts of the interim report.

An alternative performance measure, Adjusted operating result (EBIT), was added in 2025. Adjusted EBIT is defined as EBIT excluding LTIP and CEO transition related costs.

ADJUSTED OPERATING RESULT

SEK 000'	Jan – Mar		Jan – Dec
	2026	2025	2025
EBIT	-13 466	-12 697	-46 757
LTIP related costs	77	7 134	8 172
CEO transition costs	–	–	12 086
Adjusted EBIT	-13 389	-5 563	-26 499

Note 2 | Estimates and assessments

Estimates and assessments are evaluated on an ongoing basis and are based on historical experience and other factors, including expectations of future events that are considered reasonable under prevailing conditions. There has been no change in the estimates and judgments made in the Annual Report for 2025.

Note 3 | Information regarding operating segments

The Group's operations are divided into operating segments based on the parts of the business the Company's highest executive decision-maker follows up, so called "management approach". The Group's internal reporting is based on the Group management following up the operation as a whole. Based on its internal reporting, the Group has identified that the Group has only one segment.

NET SALES BY GEOGRAPHIC MARKET

SEK 000'	Jan – Mar		Jan – Dec
	2026	2025	2025
USA	36 879	44 493	180 159
TOTAL	36 879	44 493	180 159

Income from external customers has been attributed to individual countries from which the sales have taken place. As of January 1, 2024, the only country in which such sales are taking place is the USA and only within the product category Orthobiologics. The Group's fixed assets are located to Sweden, the U.K. and the U.S.

NET SALES BY PRODUCT CATEGORY

SEK 000'	Jan – Mar		Jan – Dec
	2026	2025	2025
Orthobiologics	36 879	44 493	180 159
TOTAL	36 879	44 493	180 159

Note 4 | Equity

The share capital of the Parent Company consists only of fully paid ordinary shares with a nominal (quota value) value of SEK 0.0625 / share. The company has 110 625 913 class A shares.

	2026	2025
	Jan 1 – Mar 31	Jan 1 – Mar 31
Subscribed and paid shares		
At the beginning of the period	110 625 913	97 658 920
Directed share issue	–	–
Shares from exercise of warrant program	–	–
Subscribed and paid shares	110 625 913	97 658 920
Shares for share-based payments	–	–
SUM AT THE END OF THE PERIOD	110 625 913	97 658 920

Amounts received for issued shares in addition to the nominal value during the year (premium) are included in the item "Other contributed capital", after deduction for registration and other similar fees and after deduction for attributable tax benefits.

Signatures

The Board of Directors and the CEO provide their assurance that this interim report provides an accurate view of the operations, position and earning of the Group and the Parent Company, and that it also describes the principal risks and uncertainties faced by the Parent Company and the companies included within the Group.

This report has been prepared in both a Swedish and an English version. In the event of any discrepancy between the two, the Swedish version shall apply. This report has not been audited.

Financial calendar 2026

Annual General Meeting	June 9
Interim Report Q2, 2026	August 18
Interim Report Q3, 2026	November 3
Year-end Report, 2026	February 9, 2027

OSSDSIGN AB – UPPSALA MAY 5, 2026

Simon Cartmell
Chairman of the Board

Jill Schiaparelli
Board member

Christer Fåhraeus
Board member

David Jern
Board member

Tomas Blomquist
Board member

Mark Waugh
CEO



OSSDSIGN®

OssDsign AB, Ulls väg 29C, 756 51 Uppsala, Sweden

info@ossdsign.com

ossdsign.com



CONTACT

Mark Waugh, CEO

+1 260-804-1342

mark.waugh@ossdsign.com

Anders Svensson, CFO

+46(0)70-272 96 40

anders.svensson@ossdsign.com